Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
done, good luck
In the quarterly disclosure report that was filed yesterday, Fansfrenzy changed its business operations:
FansFrenzy (OTC: FFZY) is a company that leverages its position as a publicly traded corporation to acquire and hold
undervalued assets as well as to participate and develop those assets and operating businesses. The company relies
on a deep bench of corporate and financial expertise to bring out the intrinsic value.
The company also intends to pursue a strategy of acquisition of undervalued assets. This new development is the
result of a strategic analysis in which the company concluded that greater shareholder value can be achieved.
In the past quarter 1.7 million shares were issued (again all restricted) in exchange for cash. The balance sheet is completely clean and ready to shove in a new business activity.
I still think it's sports related (teaming up with BetRegal) and the "undervalued assets" are sports teams and players. For instance they buy a hockey team in Canada, invest in that team buying new talents etcetera. Well, what do I know, let's see what happens.
Almost there!
So, what DO we know about revenue? Fact is they made $180,457 for the year ending June 30 2021. I love facts
I warned you guys for whats happening, this company is for losers only and it goes back a long time:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=108778831
So instead of only scanning headlines, read the full stories. In the first sentence: Halberd announces the filing of a provisional patent APPLICATION with the…….
Halberd Files Provisional Patent on Breakthrough Obesity Treatment
Press Release | 10/25/2021
JACKSON CENTER, PA / ACCESSWIRE / October 25, 2021 / Halberd Corporation (OTC PINK:HALB) announces the filing of a provisional patent application with the US Patent and Trademark Office covering their extracorporeal removal from the blood of patients of the various proteins, cytokines and antigens associated with obesity. Removal of these obesity-related target elements would reduce or eliminate the negative health issues associated with obesity.
Halberd's researchers have discovered certain inflammatory cytokines associated with PTSD and Alzheimer's Disease are also linked to the propensity for obesity when present in the blood. Halberd's work in eliminating antigens, inflammatory cytokines and excitatory neurotransmitters from Cerebral Spinal Fluid (CSF) for the treatment of PTSD, and from CSF and blood for the treatment of Alzheimer's Disease, provided the foundational work for this additional benefit relative to the treatment of obesity. It is believed that reduction of these elements could finally unlock the secret of why some people can eat anything and never seem to gain weight, while others struggle to maintain or lose weight with fad diets, pills and huge costs.
William A. Hartman, Chairman, President and CEO of Halberd Corporation, stated "It is envisioned that the treatment process would be as simple and as easy as donating blood, and should be just as safe. In a clinical setting, the patient would have a needle inserted into a vein in their arm through which the blood would flow through the extracorporeal treatment device where the targeted elements would be cleansed from the blood before being returned to the patient's arm. The process is expected to take 30-60 minutes per treatment and, several treatments may be required to achieve the desired result. Research on this project is expected to begin immediately in parallel with Halberd's current on-going work on PTSD and Alzheimer's disease with Halberd's university partners. Far from diverting attention from our PTSD and Alzheimer's initiatives, this is merely another adaptation of our patented extracorporeal technology and its multiplicity of applications. An update on our progress will be issued as we achieve program milestones."
https://www.otcmarkets.com/stock/HALB/news/Halberd-Files-Provisional-Patent-on-Breakthrough-Obesity-Treatment?id=326970
this press release is total nonsense, what does it say???? Stargaze has no products, nothing. Read that press release another time and tell me what's the benefit
Halberd's PTSD/Alzheimer's R&D Reveals Link to Potential Obesity Cure
Press Release | 10/20/2021
JACKSON CENTER, PA / ACCESSWIRE / October 20, 2021 / Halberd Corporation's (OTC PINK:HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer's Disease, and other neurodegenerative diseases has led to a potential breakthrough in the battle against obesity. Research has indicated inflammatory cytokines present in the Cerebral Spinal Fluid (CSF) of neurodegenerative disease patients are also found in the blood of those suffering from obesity.
Halberd's patent-pending extracorporeal treatment for removing the disease antigens, excess proteins and cytokines from CSF associated with neurodegenerative diseases can similarly be applied to eliminating the chemical imbalances in blood believed to be responsible for obesity. Removal of these elements from blood would therefore reduce or eliminate the negative health issues associated with obesity, such as high blood pressure, diabetes, heart disease, stroke, cancer, etc. It has been known for several years that obesity is linked to higher risks of death.
Further research is underway with Halberd's university partners.
William A. Hartman, Chairman, President and CEO of Halberd Corporation, stated, "Our plans to pursue cures for PTSD and Alzheimer's Disease involve the removal of select inflammatory cytokines from CSF and blood plasma. We are rapidly pursuing elimination of these target pathogens from CSF and intend to address removal from blood plasma as soon as possible. What is exciting about this development concerning obesity is that our scientists didn't have to initiate any new experimentations, but rather relied on numerous medical articles to affirm our direction
https://www.otcmarkets.com/stock/HALB/news/Halberds-PTSDAlzheimers-RD-Reveals-Link-to-Potential-Obesity-Cure?id=326316
think Pink Current again this week
even after yesterdays' haircut STGZ still has a 63 million marketcap, hahahahahahahahahahhahahahah
take a look at the assets they bought from HPIL, well???
at 0.01 STGZ would still have a 6.8 million market cap, for what???
HILARIOUS
(STGZ has an O/S of 680 MILLION shares, as soon as the restriction ends they will dump them, be careful)
In the quarterly disclosure report that was filed yesterday, Fansfrenzy changed its business operations:
FansFrenzy (OTC: FFZY) is a company that leverages its position as a publicly traded corporation to acquire and hold
undervalued assets as well as to participate and develop those assets and operating businesses. The company relies
on a deep bench of corporate and financial expertise to bring out the intrinsic value.
The company also intends to pursue a strategy of acquisition of undervalued assets. This new development is the
result of a strategic analysis in which the company concluded that greater shareholder value can be achieved.
In the past quarter 1.7 million shares were issued (again all restricted) in exchange for cash. The balance sheet is completely clean and ready to shove in a new business activity.
I still think it's sports related (teaming up with BetRegal) and the "undervalued assets" are sports teams and players. For instance they buy a hockey team in Canada, invest in that team buying new talents etcetera. Well, what do I know, let's see what happens.
2 days late, but they filed the financial report, read it and you know what's coming: GET IN, THIS WILL BE VERY REWARDING
This is an old message from 2014 about Tony Green, nothing changed....
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=108778831
In 2016-2019 I wrote a few hundred messages about STGZ and I quit that and sold when I found out that they were NOT building a multi-media company, it was all bull. So, am I surprised they made this "deal" with HPIL? No, not really. They're paying with 60 million shares for what? And why did STGZ issue 350 million shares last quarter? The OS increased from 331 million to 681 million shares. STGZ now has a market cap of $116 million.
Anyway, be careful, at the moment most shares are restricted, but not for long. Watch what happens when Tony Green, Nik Tsoukalas and Nicolas Kanellopoulos start selling...........
https://www.otcmarkets.com/stock/HPIL/financials
Nope, it's the company that will be merged in, my guess is Betregal.net. CEO Bernie Nicholls joined them as ambassador:
https://twitter.com/bernienicholls9
looks very strong lately, watch the fins that are due 10/15 for clues
Halberd Corporation CEO Letter
JACKSON CENTER, PA / ACCESSWIRE / October 7, 2021 /
Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC PINK:HALB)
This past quarter, Halberd has made some very significant and unparalleled achievements developing treatments for neurodegenerative diseases, such as PTSD/ CTE (Post Traumatic Stress Disorder/Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.
As reported in the last quarterly update, our research led us to investigate RF (Radio Frequency) and laser exposure, as the two patent-pending extracorporeal methods to eliminate targeted disease antigens. Our results this past quarter have been successful beyond our expectations. Our patented methodology has successfully eliminated Phosphorylated Tau from CSF (Cerebral Spinal Fluid). Phosphorylated Tau is believed to be the principal contributor to neurofibrillary tangles linked to Alzheimer's Disease related cognitive degeneration. Our scientists and research partners are confident that by eliminating this antigen, which we have accomplished in vitro, cognitive degeneration will be reduced, if not eliminated. Due to our laboratory success in eradicating Phosphorylated Tau, we are confident we will be successful in eliminating the remaining similar-sized target antigens and inflammatory cytokines linked to Alzheimer's Disease.
Halberd, through its research partner, Youngstown State University (YSU), successfully eliminated E.coli from buffer solution through RF and separately through laser radiation. This work continues, and will be expanding in the fourth quarter to evaluate elimination from bodily fluids. E.coli's presence in CSF is responsible for meningitis, and E.coli in blood is responsible for blood sepsis. Combined, these two afflictions are responsible for the deaths of an estimated 750,000 people each year in the US alone. Our scientists and research partners target the elimination of such deaths through our patented methodology.
In dealing with each disease state, we carefully calibrate the RF generator as well as the laser frequency regarding factors such as temperature, time exposure, particle size and other factors in order to ensure elimination of each disease antigen. Additionally, in each calibration, often disease specific, our scientists adjust the number of antibodies vis-à-vis antigens to determine the ideal eradication calibration.
With each success, we move closer to our goal - universal disease eradication through our patented extracorporeal methodology.
Our work in the coming quarter will center on elimination of the remaining antigens and inflammatory cytokines associated with the above neurodegenerative diseases and other diseases. As in other industries, our continuing work has been plagued by ongoing supply shortages, resulting in long delays of our planned research and development. We will continue to strive to address these shortages and move to mitigate delays.
STOCK PERFORMANCE
Halberd's fiscal year concluded July 31, 2021. Documentation for the periods prior to the placement of the current management team delayed submission of the appropriate material to the auditors until mid-September 2021. Recent SEC/FINRA actions to delist non-reporting companies have caused a huge demand for auditor services, thereby delaying approval of our financial package. We are doing everything possible to move this along and up-list to OTCQB. The Form 10 drafting has been sourced to an attorney and will be completed once the audit concludes. Listing on additional stock exchanges will be considered once we complete the up-listing on OTCQB.
Q3 OBJECTIVES AND ACCOMPLISHMENTS RECAP
* Establish proof-of concept for eradication of E. Coli via RF and laser as the initial steps toward development of an Alzheimer's Disease treatment. Proof of concept established.
* Conduct further laboratory development, fine tuning, and demonstration of the effectiveness of our application of the extracorporeal capture and removal of disease antigens without the need for metallic nanoparticles. (Details to be provided pending patent application filings). Dedicated prototypes are in the process of manufacture, but testing has been replaced by the ongoing and very promising laser and RF eradication of neurodegenerative disease antigens.
* Launch immune support product to the market. Launched Vita-Shield-MaxTM Immune Support product on our website, www.vitashieldmax.com, and on Amazon.
* Complete application for up-listing HALB to OTCQB index. Pending audit approval.
* Complete application for Halberd Corp.'s listing on one of the Canadian stock exchanges. Pending audit approval and up-listing to OTCQB.
Q4 OBJECTIVES
* Successfully eradicate the inflammatory cytokines, IL-6 and TNF-alpha, from Cerebral Spinal Fluid. These two cytokines are believed to be the principal causation of suicide ideation associated with PTSD.
* Presentations to the NFL, DARPA and the military outlining our achievements in elimination of the inflammatory cytokines believed to be associated with suicide ideation and PTSD and seek their support/endorsement/participation in and for our continuing study.
* Continue efforts to successfully eradicate other identified antigens and inflammatory cytokines associated with Alzheimer's Disease, Parkinson's Disease, etc.
* Continue to strengthen our Intellectual Property position through additional provisional patent applications and conversion of past provisional applications into patent applications and patents. NOTE_ Halberd Corporation has three existing patents and has filed eleven provisional patent applications to date. Our continuing strategy is to aggressively develop intellectual property.
* Continue to expand the number and breadth of scientific experts on Halberd's team to enhance our successes in the future.
SUMMARY
Halberd continues to strive to deliver maximum value to our shareholders by focusing on the prominent health issues not adequately addressed by other biomedical or pharmaceutical interests. Our current focus on developing treatments for PTSD, CTE, and Alzheimer's Disease reflects that commitment. Since 9/11, four times as many military personnel have committed suicide than have been killed in combat. Careers in contact sports have also produced alarming numbers of suicides associated with neurodegenerative diseases. Alzheimer's Disease is reportedly the seventh leading cause of death in the US.
We believe that Halberd's scientists, using our technology and expertise, are equipped to develop successful treatments for these neurodegenerative diseases which plague our military, professional athletes and our people in general.
Sincerely,
https://www.accesswire.com/666784/Halberd-Corporation-CEO-Letter
Great investment, think you're in just in time. I'm pretty sure BetRegal.net is the new activity and that's BIG. I don't think another company will be shoved in, because in recent months old debt in the "old fansfrenzy" was swapped for stock. If FFZY would be used as a SPAC everybody would lose his shares (RS) and that's not the case. As you know CEO Bernie Nicholls owns 2.5 million shares as well. The balance sheet is almost clean, except for that "notes payable" of $1,279,724 per 05/31/2021 to Giuseppe Gentile, who once owned the majority stock and still is a large shareholder (5.15%).
In 2 weeks we get the next quarterly fins that will tell more. They need funding to kick off for a good start. Also they need launching partners and as you know Bernie knows his way around in sports.
Good luck!
the .07's are standing in the way
What happened to their new IR/PR firm? Don't tell me you spend money on such a poorly written PR. Like the news though, but pay for pro writers
Don't hold your breath. First they need to file with the SEC a Form 10. No filing yet. Also OTC needs more than a week to process the docs. So, forget it.
(by the way, check Movements CIK code 0001121130, Visualmed Clinical Systems)
https://sec.report/CIK/0001121130
$HALB ignorance is bliss
Found this on another message board:
9/19/21, 01:10 PM
$HALB
we know that the inflammatory cytokines IL-6 and TNF-alpha are key factors in developing Alzheimer's, but these suckers also stimulate the development of obesity, type2 diabetes and metabolic disturbances; if HALB succeeds eradicating the inflammatory cytokines from CSF, they not only have the solution to treat AD but many more diseases; just google IL-6 and TNF-alpha
"The development of obesity and related disorders, e.g., type II diabetes (T2D), hypertension, and metabolic disturbances is strongly related to increased levels in proinflammatory cytokines (IL-1, IL-6, and TNF-a). Both IL-6 and TNF-a are secreted by adipocytes and their concentration correlates with the percentage and distribution of fat tissue in the body. Both cytokines are the main factors responsible for the induction of acute phase proteins production (e.g., CRP) and to inflammatory state."
Last week $HALB started experimentation at YSU eradicating IL-6 and TNF-Alpha from CSF. Testing to be concluded this week. More news coming. Amazing technology, fully patented and/or provisional patent applications pending. Most undervalued biotech company listed on OTC. JMO
thanks, I've seen it, if he does it again for no reason I'll report him to Ihub Admin
Hi, the booster Vita Shield Max does not need FDA approval. They have plans to produce a second version containing Naltrexone and if they do, then they need FDA approval for only that product.
they don't need FDA approval for the booster
Fansfrenzy Corp has a great share structure, with an O/S of 53 million, restricted 43 million and a free float per 05/31/2021 of 9.8 million shares only. FFZY filed all missing fins and attorney letter in the past month and is Pink Current OTC.
CEO Bernie Nicholls (former LA Kings legend) joined BetRegal about a month ago as ambassador, together with his friends Damon Allen and Matt Dunigan.
BetRegal has 3 sites: BetRegal.com (world), BetRegal.ca (Canada) and BetRegal.net, which has all features Bernie Nicholls wanted to have in the Fansfrenzy website: free play sportsbook, free contests (win prizes, like apparel and tickets for NHL, NBA etc), free casino (games, slot machines etc) and a news feed. What will be added is "BetRegal in the community", bringing fans and communities (colleges, professional sports teams etc) together.
Some links:
https://betregal.net/
https://twitter.com/bernienicholls9
Big things coming. Fansfrenzy did not spend a lot of money to get current and then do nothing. Watch what happens when BetRegal/FFZY start communicating about their plans, with a tiny float of 9.8 million shares this will fly way beyond what we've see recently. Buy and hold. AND DO YOUR OWN DD
You've been following HALB for more than a decade, great, you like beer pumps and drones?
As you know new management started in early 2020, building on patents and IP developed at BIEI. Look at Biogen, they failed with Gosuranemab and Aduhelm (though on the market after FDA clearance) is not much better. Next stage in HALB's experimentation this month is the eradication from CSF of the two inflammatory cytokines IL-6 and TNF-alpha, that may be the cure to PTSD and CTE. Removal of other AD-building blocks Beta-amyloid and TAU later this month.
HALB on WKBN news:
Halberd Corp eradicates (for virtually 100%) the main building block (P-TAU) of ALZHEIMER'S DISEASE from CSF in fully patented extracorporeal treatment, experimentation at ASU and YSU. Same treatment applies to Tau, Beta-Amyloid and the inflammatory cytokines IL-6, TNF-alpha and so on
https://www.accesswire.com/viewarticle.aspx?id=663682
Halberd Corp eradicates (for virtually 100%) the main building block (P-TAU) of ALZHEIMER'S DISEASE from CSF in fully patented extracorporeal treatment, experimentation at ASU and YSU. Same treatment applies to Tau, Beta-Amyloid and the inflammatory cytokines IL-6, TNF-alpha and so on
https://www.accesswire.com/viewarticle.aspx?id=663682
$HALB 0.03 OS 511MM float 280MM market cap 15MM
Halberd Corp eradicates (for virtually 100%) the main building block of ALZHEIMERS DISEASE in fully patented extracorporeal treatment, tests at Arizona State University and Youngstown State University
https://www.accesswire.com/viewarticle.aspx?id=663682
$HALB 0.03 OS 511MM float 280MM market cap 15MM
Halberd Corp eradicates (for virtually 100%) the main building block of ALZHEIMERS DISEASE in fully patented extracorporeal treatment, tests at Arizona State University and Youngstown State University
https://www.accesswire.com/viewarticle.aspx?id=663682
Halberd's Treatment Eradicates Primary Building Block of Alzheimer’s Disease
Monday, September 13, 2021 8:00 AM
JACKSON CENTER, PA / ACCESSWIRE / September 13, 2021 / Halberd Corporation (OTC PINK:HALB) has successfully eradicated the primary building block of neurofibrillary tangles of Alzheimer's Disease from test fluids in laboratory testing. Through its patented extracorporeal process in combination with its patent-pending laser eradication process, replication tests conducted at Youngstown State University (YSU) achieved virtually 100% elimination of the Phosphorylated Tau antigen, which is related to the onset and progression of Alzheimer's Disease and other neurodegenerative diseases!
Dr. William G. Sturrus, Chair of the Physics, Astronomy, Geology and Earth Sciences Department at Youngstown State University, who is overseeing YSU's eradication testing exclaimed, "Through our earlier, carefully constructed experimentations, we determined the correct combination of factors that can now be replicated to eliminate this target disease antigen from test fluid. The fluid is treated with a specific antibody conjoined to appropriately sized metallic nanoparticles. The antibody is designed with a strong affinity for the disease antigen and attaches itself to the target antigen. The conjoined nanoparticle/antibody/antigen is then exposed to a programed burst of the proper laser light frequency. The laser light excites the nanoparticles, thus generating a sufficient level of heat to destroy the target disease antigen, resulting in elimination of the disease pathogen."
William A. Hartman, Halberd Corporation's Chairman, President & CEO, stated, "We are beyond ecstatic with the demonstrated elimination of the Alzheimer's Disease target antigen in our testing to date, thus establishing proof-of-concept! Inasmuch as our testing has successfully determined the critical control variables and application sequences, we believe that we will be successful in eliminating the remaining Alzheimer's Disease-related antigens and inflammatory cytokines in the laboratory. At the conclusion of the interim tests with the inflammatory cytokines, IL-6 and TNF-alpha, which are the principal causal factors of PTSD and CTE (Chronic Traumatic Encephalopathy), we plan to further our discussions with the military and various sports organizations regarding our findings, and offer them the opportunity to participate in the advancement of this promising technology."
Hartman continued, "Following the conclusion of all related laboratory experiments, we plan to initiate in-vivo animal tests. Our progress in this regard will be published in subsequent press releases as well as our quarterly CEO Newsletter."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
So do I. People following $HALB and doing some DD know what's coming, think it will be today. Good luck
Vita Shield Max will be available on Amazon by the end of the week
Hi, did you check CEO Bernie Nicholls:
https://www. betregal.net
$FFZY went Pink Current today
Very interesting share structure: OS 53 million and Float 9.8 million
CEO Bernie Nicholls joint BetRegal.net last month as ambassador. If Fansfrenzy turns into a sports betting site it will go to dollars, do your DD
Yes, next week?